FDA WARNING_LETTER - LVWellness & Aesthetics - October 15, 2020
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
On October 15, 2020, the FDA issued a Warning Letter to LVWell, LLC, following a review of their websites (www.lvwell.com and www.facebook.com/lvwellnessaesthetics/) since August 5, 2020. The FDA observed the sale of products claiming to mitigate, prevent, treat, diagnose, or cure COVID-19, which are unapproved, adulterated, and misbranded.
Specifically, the "COVID-19 ANTIBODY TEST KIT" is cited as an adulterated device under section 501(f)(1)(B) of the FD&C Act (21 U.S.C. § 351(f)(1)(B)) due to the lack of an approved premarket approval (PMA) or investigational device exemption (IDE). It is also misbranded under section 502(o) (21 U.S.C. § 352(o)) for failure to notify the agency of intent to introduce the device into commercial distribution. The FDA emphasizes that no COVID-19 serology test for at-home use has been approved, cleared, or authorized.
Additionally, the "ViraFend Multi-Virus Defense" product is identified as an unapproved new drug sold in violation of section 505(a) (21 U.S.C. § 3
ID · 3182473e-d885-41c5-9618-774c61dbf73b
Full citation text and observation details available on the Dashboard.